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The natural history of azathioprine compliance after renal are complicated, and it is likely that the patient’s dis-
transplantation. charge to home routinely produces drug errors, despite
Background. Successful renal transplantation requires long- intensive patient education efforts. Indeed, with gentleterm adherence to complex medical regimens, yet knowledge
prodding, many patients candidly admit minor or grossof post-transplant medication compliance is still inadequate.
deviations from their medication schedule [1–4]. How-Methods. The natural history of medication compliance was
quantitatively documented using electronic medicine bottle ever, levels of medication noncompliance and their asso-
monitors. Azathioprine use was recorded with medication ciation with adverse renal transplantation outcomes are
monitors beginning at hospital discharge in a prospective co- unknown.
hort of 180 renal transplant recipients. These patients and 87
New and more potent immunosuppressive agents haveother eligible patients, declining study participation, were fol-
reduced allograft loss, and now rejection more typicallylowed up to five years. Compliance rates were associated with
discrete clinical outcomes: acute rejection, allograft loss, and appears later in the clinical course. After rejection and
death. infection, medication noncompliance was cited as the
Results. During the first six months, only 8% of all azathio- third most common cause of graft loss [5]. However, the
prine doses were missed. However, individual compliance rates clinical definition and assessment of medication compli-varied widely, ranging from 16 to 100%, and each month, on
ance are problematic [6–8]. At best, patient reports oraverage, 18% of patients skipped medication for four or more
pill counts gauge average compliance, but both sufferdays. Outcome events were not different between study partici-
pants and those refusing study. However, lower compliance from reliability problems [8–11]. Drug levels can only
rates during the first six months were associated in a “dose- be measured episodically and may be acutely influenced
response” fashion with acute rejection (P 0.006) and allograft by patient dosing behavior [12, 13]. Other clinical compli-loss (P  0.002). Declining compliance during the first 90 days
ance measures (weight gain, clinic attendance, etc.) oftenwas a strong risk factor both for later acute rejection (odds
incorporate complex variables that are not completelyratio  13.9, 95% CI, 2.9 to 68, P  0.001), and allograft loss
(odds ratio  4.3, 95% CI, 1.1 to 16, P  0.032). under the patient’s control [1, 14]. With few exceptions
Conclusions. Electronic monitoring provides a temporal de- [15], compliance studies in transplant patients are retro-
scription and quantitation of medication compliance. Reduced spective, so the natural history of compliance patterns
azathioprine compliance was highly associated with acute rejec-
cannot be linked readily with outcomes.tion and allograft loss. Trends in early compliance behavior
Electronic monitors sealed in medicine bottle capspredict later outcomes, thus providing unique opportunities
for intervention. have been used to track medication compliance in di-
verse medical settings [16–21], including organ trans-
plantation [22, 23]. Such devices produce a precise time
record of each cap opening, and this has generally beenThe outpatient medication regimens following renal
accepted as a proxy for medication ingestion.transplantation are typical of the complex regimens
This prospective study employed electronic monitorsmany patients with other chronic conditions are expected
to quantitate the natural history of post-transplant medi-to follow. Postoperative transplant medication schedules
cation compliance and examined the predictive value of
noncompliance for adverse outcomes.
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versity of Minnesota and were discharged with a func- charge after transplant surgery, was compiled for each
study patient. Each cap removal was presumed to repre-tioning graft. All eligible patients received azathioprine
tablets as part of their immunosuppressive regimen and sent the patient ingesting one dose of azathioprine.
were responsible for their own medication administra-
Compliance definitiontion. Seventy-two of these patients were discharged be-
fore they could be invited to participate, and 47 were Azathioprine was usually prescribed as a single daily
dose. Dosage changes were identified by review of eachdeemed ineligible because of language barriers, use of
azathioprine suspension, or care setting (for example, patient’s medical record. All study days, beginning at
initial hospital discharge up to study termination (duenursing home). One hundred eighty (67.4%) of the 267
eligible patients agreed to enroll, and 87 declined study to patient dropout, patient death, or study completion),
were divided into three mutually exclusive categories:participation (nonparticipants).
Patients recruited to this study (participants) were told missing, compliant, or noncompliant. Missing data days
were defined as those when a patient either was hospital-their azathioprine use was being monitored to assess the
impact of drug dose timing on immunosuppression. The ized, the monitor cap malfunctioned, or it was physically
lost. Since no reliable estimation of compliance was pos-medication monitor records were maintained separately
from clinical records, so compliance information was sible for missing data days, they were excluded. All of
the remaining days were evaluable as compliant or non-never available to influence any clinical decisions regard-
ing medication dosing, transplant kidney biopsy, or hos- compliant and provided the data for analyses. Days were
deemed as compliant if on that day there were the pre-pitalization. This study was approved by the University
of Minnesota Institutional Review Board and was re- scribed number of cap openings, between 3:00 a.m. that
morning and 2:59 a.m. the next day. This interval wasviewed annually.
chosen to minimize confusion when patients took their
Outcomes azathioprine after midnight. A noncompliant day was
one when there was no cap opening during this 24-hourAll 267 eligible patients were followed prospectively
for acute rejection, allograft survival, and patient sur- interval.
Time after hospital discharge was measured in 30-vival. Outcome events occurring in the first 90 days fol-
lowing initial post-transplant hospital discharge were day increments (months). Each month had to contain a
minimum of 15 evaluable days of cap data to be consid-designated as early and those after 90 days were desig-
nated as later. Acute rejection was diagnosed in kidney ered adequate for analysis. Monthly compliance rates
were expressed as the percentage of compliant days perbiopsy or nephrectomy specimens by the Banff criteria
[24]. When a tissue diagnosis was not available, the acute evaluable days in that month.
rejection diagnosis was based on an otherwise unex-
Statistical methodsplained elevation of creatinine, coupled with clinical
signs (such as fever, hypertension, or oliguria). Time to Demographic factors and outcomes were compared
using chi-square or Fisher’s exact test; continuous demo-graft loss was based on the date of retransplantation or
resumption of regular dialysis treatments. Death was graphic variables were compared with two-sample t tests.
Kaplan-Meier estimates of time to event were compareddefined as a graft loss, regardless of renal function at the
time of death. between groups using the Wilcoxon test. Statistical sig-
nificance was assumed at P  0.05, but exact P values
Electronic medication monitors are presented whenever the value was less than 0.20.
Logistic regression was used to compare odds of out-Study patients received their azathioprine tablets in
a medication vial with an electronic monitor sealed in comes between compliance subgroups adjusting for age,
gender, race, diabetes, donated kidney source, and earlythe vial cap (Medication Event Management System,
MEMS TrackCap; Aprex Corp., Union City, CA, USA). rejection. All analyses were performed using SAS (re-
lease 6.12, 1996; SAS Institute, Cary, NC, USA).These caps contained a battery and microelectronic cir-
cuitry generating a date and time record each time the
cap was removed. The monitor caps were exchanged by
RESULTS
mail every three to six months.
Demographics: Participants and nonparticipantsIndividual dosing records were downloaded from the
caps to a personal computer that had proprietary soft- The 180 study participants and the 87 nonparticipants
were similar in age, gender, race, kidney donor source,ware that decoded the monitor data and filtered out
multiple openings within a 15-minute interval, as might and the presence or absence of diabetes (Table 1). Al-
though the initial length of hospital stay was shorteroccur when a patient fumbles with the cap or briefly
delays replacing the cap. A cumulative record of cap for participants, both groups had similar frequencies of
delayed graft function and early rejection. Follow-upopenings, beginning on the day after the hospital dis-
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Table 1. Demographic characteristics and outcomes of the Natural history of medication compliance in the first
267 patients eligible to participate in the study
six months after discharge
Non- There were in aggregate 24,120 possible dose days inParticipants participants P valuea
the first six months for the 134 participants with adequate
Patients 180 87
data. Patients were hospitalized or the data were missingMales 102 (57%) 45 (52%) NS
White 156 (87%) 76 (87%) NS for 2002 days (8.5%), leaving a total of 21,644 evaluable
Diabetic 61 (34%) 34 (39%) NS days. For nine patients who experienced an outcome
Living donor kidney 99 (55%) 54 (62%) NS
event during months 4 to 6, their compliance data afterAge at transplant years 42 (13.7) 44 (13.9) NSb
Young 21 years old 8 (4%) 6 (7%) NSc that event were censored (Table 2).
Initial hospital stay after Substantial noncompliance with azathioprine (skipped
transplant days 9 (4.7) 12 (7.2) 0.008b
dose days) was seen as early as the first month afterFollow-up months 50 (12) 46 (13) 0.015
Events discharge. Slightly more than half of the patients skipped
Early acute rejection 40 (22%) 22 (26%) NS no doses each month, but nearly 18% of patients missed
Later acute rejection 27 (15%) 14 (16%) NS
four or more days of medication (Table 2 and Fig. 1).Rejection rate (SE) 4.2 (0.8) 4.9 (1.3) NSb
Graft loss 30 (17%) 16 (18%) NS During the first six months, skipped azathioprine doses
Loss rate (SE) 4.4 (0.8) 5.2 (1.3) NS averaged a total of 13 days (8%).Later graft loss 26 (14%) 14 (16%) NSb
Ranking patients’ six-month average compliance (per-Death 12 (7%) 9 (10%) NS
Death rate (SE) 1.6 (0.5) 2.8 (0.9) NS centage of days with at least one dose of azathioprine),
Later death 10 (6%) 9 (10%) NSb the compliance rates were quite good (median, 97.2%;
Numbers are frequency (percent), or average ( standard deviation). “Early” range, 16 to 100%). Twenty percent of patients tookevents occurred within 90 days of hospital discharge after transplant, while
“Later” events occurred 90 days or more after discharge. Event rates are numbers less than 90% of their prescribed azathioprine, with one
of events per 100 patient-years. NS is not significant. patient missing 149 doses over 180 days. Acute rejectiona Comparisons between groups by chi-squared test unless otherwise noted
b Two-sample t test was significantly related to compliance quartiles. No pa-
c Fisher’s exact test, two-tailed tient in the best compliance quartile experienced rejec-
tion, while the rates of rejection in those quartiles with
worsening compliance were 12, 18, and 29%, respec-
tively. When noncompliance was defined by extra dosesaveraged four years for all eligible patients, but was
alone, there was no association with acute rejection rates;slightly longer for participants (Table 1).
based on these findings, subsequent analyses focused on
skipped dose noncompliance.Outcomes: Participants and nonparticipants
Figure 2 shows the Kaplan-Meier actuarial estimate
There were a total of 103 episodes of acute rejection, of rejection-free survival and demonstrates earlier and
with 62 early rejections and 41 later rejections among more frequent rejection directly related to the compli-
the 267 eligible patients followed through July 1, 1998. ance quartile (P  0.006). Also, the actuarial estimates
Additionally, 46 renal allografts were lost, and 21 pa- comparing the best and worst compliance quartiles docu-
tients died (Table 1). Although nonparticipants had nu- mented that graft loss was increased in patients with the
merically higher frequencies and rates for all clinical poorest compliance (P  0.002). Death was an infre-
events, these differences were not significant (Table 1). quent event (N  5) and not clearly associated with
Kaplan-Meier estimates of time to each outcome were compliance.
also not significantly different between these two groups Although the risk of acute rejection and graft loss was
(data not shown). associated with poor compliance, the compliance rate
was not very sensitive at predicting clinical outcomes,
Patients with adequate early data mainly because there were few informative events among
Adequate data for at least two of the first three months the 134 patients even when followed out to four years.
were available for 134 (74%) of the participants. Forty- Post hoc statistical models predicting clinical outcome
six participants had incomplete data for various reasons based on compliance rate and adjusted for demographic
including: missing data (N  21), dropping out of the characteristics led to the identification of a patient sub-
study (21), death (2), and loss of graft function (2) during group with a significantly higher rate of later acute rejec-
the first 90 days. There were no demographic differences tion. These were patients with early declining compliance
between the 134 participants with adequate data and the (N19), specifically those who during the second month
46 other participants, but a larger proportion of patients skipped at least two more days of medication than in
with inadequate data were non-white (22%) compared their first month after discharge.
with 10% of the 134 adequate data participants (chi- The demographics in the declining compliance group
were similar to patients with steady compliance, exceptsquare, P  0.064).
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Table 2. Summary of cap data for months 1–6 in 134 participants with complete data for at least two of the first three months
Month
Mean of
1 2 3 4 5 6 months 1–6
Mean compliance 87% 90% 88% 88% 88% 88% 88%
Mean skipped doses 9% 6% 7% 9% 8% 9% 8%
Mean extra doses 4% 4% 4% 4% 3% 3% 4%
Participants with no skipped
dose during month N (%) 75 (56%) 81 (60%) 68 (51%) 72 (54%) 78 (61%) 72 (57%)
Participants who skipped 4 or more
doses during month N (%) 25 (19%) 17 (13%) 24 (18%) 25 (19%) 23 (18%) 22 (18%)
Total days
Compliant days 3109 3300 3333 3234 3102 2993 19071
Noncompliant days 465 386 446 463 407 406 2573
Skipped dose 327 222 280 330 292 294 1745
Extra dose(s) 138 164 166 133 115 112 828
Evaluable days 3574 3686 3779 3697 3509 3399 21644
Days in hospital 281 306 88 41 44 55 815
Missing data days 165 28 153 237 293 311 1187
Censored days post-event 0 0 0 (45a) (174b) (255c) (474)
Total dose days 4020 4020 4020 3975 3846 3765 23646
Data presented are the monthly mean compliance rates, extra dose days and days when no drug was taken. Also given is the distribution of all the days within
the 6-month period. The superscripts indicate patient outcome events.
a One death, 1 graft loss, 2 acute rejections during month 4
b One graft loss, 2 acute rejections during month 5
c One death, 1 acute rejection during month 6
Fig. 2. Kaplan-Meier estimates of rejection-free survival beginning 90
days after the initial hospital discharge. Patients were grouped by their
compliance quartile. Note the significant differences in event rates be-
tween compliance quartiles (P  0.006). No episodes of rejection were
seen in patients in the best quartile (compliance rate 99%), and in
each of the other quartiles, declining compliance was associated withFig. 1. Monthly compliance data for the first six months following
an increasing incidence of rejection. Symbols are: () best quartile;initial hospital discharge are illustrated. Each column depicts the num-
() second quartile; ( ) third quartile; () worst quartile.ber of doses missed by each of 134 participants with complete data
that month. Each month approximately half of the patients missed no
azathioprine doses, whereas 13 to 19% of patients skipped four or more
doses. Note the relatively consistent distribution of missed doses during
the first six post-transplant months. Symbols are days without a medica-
CI, 2.9 to 68, P  0.0011). Similarly, the adjusted oddstion dose: ( ) 0 days skipped; ( ) 1 day skipped; ( ) 2 to 3 days
skipped; ( ) 4 days skipped. of graft loss were 4.3 times higher (95% CI, 1.1 to 16,
P  0.0321).
Moreover, the Kaplan-Meier estimates (Fig. 3) illus-
trate that the time to acute rejection was significantlythat there were significantly more non-whites (Table 3).
shorter for patients with declining compliance (P Both groups had similar lengths of follow-up, as well as
0.0026). Six of the seven later rejections in this subsetrates of early graft dysfunction or early acute rejection.
with declining compliance occurred within nine monthsHowever, for patients with declining compliance, the
after discharge; during that same period, only 8 of 13adjusted odds for experiencing later acute rejection were
13.9 times higher than for the steady compliers (95% rejections occurred among the 115 steady compliers.
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Table 3. Demographic characteristics and outcomes of the 134
adequate-data participants, by compliance group; numbers are
frequency (percent), or average (standard deviation)
Declining Steady
compliance compliance P valuea
Patients 19 115
Males 12 (63%) 65 (57%) NS
White 14 (74%) 106 (92%) 0.029b
Diabetic 9 (47%) 35 (30%) 0.145
Living donor kidney 12 (63%) 59 (51%) NS
Age at transplant years 43 (15.7) 43 (13.6) NSb
Young 21 years old 2 (11%) 5 (4%) NSc
Acute tubular necrosis 0 (0%) 8 (7%) NSc
Initial hospital stay after
transplant days 9 (3.8) 9 (4.9) NSb
Follow-up months 51 (11) 49 (9) NS
Events Fig. 3. Kaplan-Meier estimates of rejection-free survival beginning 90
Early acute rejection 5 (26%) 22 (19%) NS days after the initial hospital discharge. Symbols are: () patients with
Late acute rejection 7 (37%) 13 (11%) 0.004 a pattern of steady compliance (N 115); ( ) patients with declining
Rejection rate (SE) 12.8 (4.9) 3.0 (0.8) 0.005b compliance (N 19). The numbers in parentheses indicate the patients
Graft loss 5 (26%) 12 (10%) 0.054 at risk initially and annually. The curves separate promptly and differ
Loss rate (SE) 7.2 (3.2) 2.6 (0.8) 0.064b significantly (P  0.0026).
Death 1 (5%) 4 (3.5%) NS
Death rate (SE) 1.3 (1.3) 0.8 (0.4) NSb
Event rates are numbers of events per 100 patient-years. NS is not significant.
a Comparisons between groups by chi-squared test unless otherwise noted
b Two-sample t test these limitations, there was a direct association between
c Fisher’s exact test, two-tailed the six-month compliance data and the clinical outcome
events. A similar linkage also is seen in another medica-
tion monitor study of cardiac transplant patients [23].
We believe our demonstrated association exists becauseDISCUSSION
azathioprine dosing may be an effective surrogate forThis study used electronic monitoring technology to
overall medication compliance. In other words, if pa-quantitate the natural history of post-transplant medica-
tients are casual while taking a single daily dose of ation compliance. Our study also presented outcome data
drug with minimal side effects, are not they likely to beon all eligible patients, even those refusing study partici-
even less reliable following multidose drug regimens withpation. Any study that informs participants their medica-
recognizable side effects?tion compliance will be studied might be expected to
It is equally important to note that the patients withrecruit patients more likely to comply, leading to a non-
excellent compliance also experienced excellent out-representative sample. Demographic similarities, as well
comes. Indeed, the absence of acute rejection in the bestas similar outcome event rates, in participants and non-
compliance quartile suggested that efforts to substan-participants suggest minimal overt recruitment bias.
tially improve immunosuppressive drug complianceAzathioprine is a particularly easy drug to use. Given
might be as rewarding as the development of new andas a single daily dose, it has virtually no appreciable
more potent drug regimens.clinical side effects. While observed compliance levels
The level of noncompliance associated with acceptablein this study were quite good, medication compliance
outcomes during the follow-up period also was surpris-was far from perfect. Only 21 of 134 patients (16%)
ing. While rejection was more common among the morehad “perfect” compliance records, missing no doses of
noncompliant patients, the majority (70%) of patientsazathioprine over six months. On average, there was
in the worst compliance quartile did not experience any92% compliance, so an average patient missed 13 days
overt rejection. Perhaps this lack of acute rejection re-of medication over the observation period. Although it
flects the long half-life of azathioprine or the overlappingwas expected that patients would occasionally miss drug
effects of multiple immunosuppressive drugs or the lessdoses, this level of noncompliance beginning immedi-
intense immunosuppression regimens required in someately after hospital discharge was unanticipated.
patients.Azathioprine’s long biological half-life results in a very
The use of electronic monitors also allowed the explo-“forgiving” drug [6], so monitoring its daily usage is a
ration of dynamic medication compliance on a monthlyparticularly insensitive approach to linking medication
or even daily basis. Our post hoc analyses of patientsnoncompliance to outcomes. This fact coupled with aza-
experiencing acute rejection recognized an early patternthioprine’s simple dosing schedule suggests that our
of declining compliance that was associated with bothquantitative measure probably overestimated medica-
tion compliance. Thus, it is encouraging that despite acute rejection and graft loss. Other monitored drug
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trials: Relevance in the new health care environment. Adv Drugstudies also document significant early and decreasing
Res 26:238–257, 1995
compliance patterns with an inhaled bronchodilator [25], 7. Boudes P: Drug compliance in therapeutic trials: A review. Control
Clin Trial 19:257–268, 1998oral fluvastatin [21], isosorbide [19], and cyclosporine
8. Vander Stichele R: Measurement of patient compliance and the[22]. It will be critical to verify the predictive value of this
interpretation of randomized clinical trials. Eur J Clin Pharmacol
compliance variable in prospective transplant studies. If 41:27–35, 1991
9. Wright EC: Non-compliance: Or how many aunts has Matilda?confirmed, this pattern may permit the early recognition
Lancet 342:909–913, 1993of high-risk patients and could provide a valuable oppor- 10. Hilbrands LB, Hoitsma AJ, Koene RAP: Medication compliance
tunity for compliance intervention trials. after renal transplantation. Transplantation 60:914–920, 1995
11. Lee JY, Kusek JW, Greene PG, et al: Assessing medication adher-Finally, this demonstration of the importance of medi-
ence by pill count and electronic monitoring in the African Ameri-cation compliance has implications for clinical trial de- can study of kidney disease and hypertension (AASK) pilot study.
sign. Specifically, as studies of newer agents or regimens Am J Hypertens 9:719–725, 1996
12. Cramer JA, Scheyer RD, Mattson RH: Compliance declines be-proceed in solid organ transplant patients, it becomes criti-
tween clinic visits. Arch Intern Med 150:1509–1510, 1990cal to know which patients are complying with the protocol 13. Feinstein AR: On white-coat effects and the electronic monitoring
of compliance. Arch Intern Med 150:1377–1378, 1990[26]. Without such knowledge, the relationships between
14. Kiley DJ, Lam CS, Pollak R: A study of treatment complianceoutcome data and therapy are attenuated. What is more
following kidney transplantation. Transplantation 55:51–56, 1993
important, as overall results improve, ever larger “intent 15. Dew MA, Kormos RL, Roth LH, et al: Early post-transplant
medical compliance and mental health predict physical morbidityto treat” trials are needed to definitively demonstrate im-
and mortality one to three years after heart transplantation. J Heartproved transplant outcomes [27]. In this setting, recruiting
Lung Transplant 18:549–562, 1999
and including noncompliant patients increases the diffi- 16. Cramer JA, Mattson RH, Prevey ML, et al: How often is medica-
tion taken as prescribed? JAMA 261:3273–3277, 1989culty of detecting significant outcome differences [25].
17. Waterhouse DM, Calzone KA, Mele C, Brenner DE: Adher-
ence to oral tamoxifen: A comparison of patient self-report, pill
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